DE60234961D1 - Kristallform von Lercanipidin-Hydrochlorid zur Verwendung als antihypertensives Mittel - Google Patents

Kristallform von Lercanipidin-Hydrochlorid zur Verwendung als antihypertensives Mittel

Info

Publication number
DE60234961D1
DE60234961D1 DE60234961T DE60234961T DE60234961D1 DE 60234961 D1 DE60234961 D1 DE 60234961D1 DE 60234961 T DE60234961 T DE 60234961T DE 60234961 T DE60234961 T DE 60234961T DE 60234961 D1 DE60234961 D1 DE 60234961D1
Authority
DE
Germany
Prior art keywords
lercanipidin
hydrochloride
crystal form
antihypertensive agent
antihypertensive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234961T
Other languages
English (en)
Inventor
Fausto Bonifacio
Francesco Campana
Iasi Gianluca De
Amedeo Leonardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati Ireland Ltd
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60234961(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Application granted granted Critical
Publication of DE60234961D1 publication Critical patent/DE60234961D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE60234961T 2001-08-06 2002-08-05 Kristallform von Lercanipidin-Hydrochlorid zur Verwendung als antihypertensives Mittel Expired - Lifetime DE60234961D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001726A ITMI20011726A1 (it) 2001-08-06 2001-08-06 Forme polimorfe della lercanidipina cloridrato

Publications (1)

Publication Number Publication Date
DE60234961D1 true DE60234961D1 (de) 2010-02-11

Family

ID=11448245

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60234961T Expired - Lifetime DE60234961D1 (de) 2001-08-06 2002-08-05 Kristallform von Lercanipidin-Hydrochlorid zur Verwendung als antihypertensives Mittel
DE60206787T Expired - Lifetime DE60206787T2 (de) 2001-08-06 2002-08-05 Kristalline polymorphe formen von lercanidipin hydrochlorid und verfahren zu deren herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60206787T Expired - Lifetime DE60206787T2 (de) 2001-08-06 2002-08-05 Kristalline polymorphe formen von lercanidipin hydrochlorid und verfahren zu deren herstellung

Country Status (36)

Country Link
EP (4) EP1600441B1 (de)
JP (1) JP2005504045A (de)
KR (3) KR20050043992A (de)
CN (2) CN100448847C (de)
AP (1) AP1766A (de)
AR (1) AR037139A1 (de)
AT (2) ATE453624T1 (de)
AU (1) AU2002327924C1 (de)
BR (1) BR0211739A (de)
CY (2) CY1109711T1 (de)
DE (2) DE60234961D1 (de)
DK (3) DK1600441T3 (de)
EA (1) EA005673B1 (de)
EC (1) ECSP044973A (de)
ES (3) ES2334678T3 (de)
HK (3) HK1067123A1 (de)
HR (1) HRP20040156B1 (de)
HU (1) HU229563B1 (de)
IL (3) IL153917A (de)
IT (1) ITMI20011726A1 (de)
MA (1) MA27133A1 (de)
ME (2) ME01525B (de)
MX (1) MXPA04001069A (de)
NO (2) NO325541B1 (de)
NZ (2) NZ531558A (de)
OA (1) OA12648A (de)
PE (1) PE20030328A1 (de)
PL (1) PL216066B1 (de)
PT (2) PT2157083E (de)
RS (1) RS52161B (de)
SI (3) SI1432683T1 (de)
TN (1) TNSN04024A1 (de)
UA (1) UA82988C2 (de)
UY (1) UY27410A1 (de)
WO (1) WO2003014084A1 (de)
ZA (1) ZA200401806B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
AU2004294674B2 (en) * 2003-12-01 2009-02-26 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
BRPI0616169B8 (pt) 2005-09-16 2021-05-25 Glenmark Pharmaceuticals Ltd cloridrato de lercanidipina na forma polimorfa v, composição farmacêutica compreendendo dito composto e processos para preparação de cloridrato de lercanidipina
KR100821165B1 (ko) * 2006-03-10 2008-04-14 동우신테크 주식회사 레르카니디핀 염산염의 제조 방법
JP2010514753A (ja) * 2006-12-29 2010-05-06 ドンウ シンテック カンパニー リミテッド レルカニジピン塩酸塩の製造方法
WO2008107797A2 (en) * 2007-03-05 2008-09-12 Actavis Group Ptc Ehf Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
EP2585051B2 (de) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische orale dosierformen mit lercandipin und enalapril und ihren pharmazeutisch akzeptablen salzen
EP2444394A1 (de) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Verfahren zur Herstellung amorpher Formen von Lercanidipin HCl
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
US20140031557A1 (en) * 2011-04-18 2014-01-30 Hefeibeinie Medical Technology Company, Ltd. Method for purification of calcium channel blockers of dihydorpyridine type and preparation of nanoparticles thereof
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102584682A (zh) * 2011-12-31 2012-07-18 苏州二叶制药有限公司 盐酸乐卡地平的制备方法
CN103497075B (zh) * 2013-09-25 2016-03-23 山西北化关铝化工有限公司 水悬浮延期药造型粉
CN109232389B (zh) * 2018-05-15 2021-10-08 迪嘉药业集团有限公司 一种小粒度硝苯地平的结晶制备方法
CN115353485B (zh) * 2022-07-26 2024-04-19 山西双雁药业有限公司 从硝苯地平母液中回收硝苯地平的方法及应用
CN115671066B (zh) * 2022-11-21 2024-07-02 安徽宏业药业有限公司 一种盐酸乐卡地平片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596139A (en) * 1897-12-28 Process of generating acetylene gas
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
BR0108363A (pt) 2000-02-16 2004-02-10 Neurogen Corp Composto, métodos para modular função de receptor de crf e acoplado a proteìna g, para tratar um distúrbio ou doença do snc, para localizar receptores de crf em amostras de seção de tecidos, para inibir a ligação de crf a um receptor de crf¹ e para alterar a atividade de transdução de sinal de um receptor de crf¹ e composição farmacêutica
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
MA27133A1 (fr) 2005-01-03
EP2157083A3 (de) 2010-03-24
DK1600441T3 (da) 2010-02-08
WO2003014084A1 (en) 2003-02-20
NO325541B1 (no) 2008-06-16
IL153917A (en) 2005-11-20
AU2002327924B2 (en) 2008-04-24
HRP20040156A2 (en) 2004-08-31
SI1600441T1 (sl) 2010-02-26
HK1140487A1 (en) 2010-10-15
ATE307114T1 (de) 2005-11-15
IL153917A0 (en) 2003-07-31
DK2157083T3 (en) 2015-11-02
HUP0401163A3 (en) 2009-04-28
AP2004002989A0 (en) 2004-03-31
UA82988C2 (uk) 2008-06-10
ES2212759T3 (es) 2006-04-16
KR20050111799A (ko) 2005-11-28
EA200400280A1 (ru) 2004-08-26
DE60206787T2 (de) 2006-07-13
CN101475524A (zh) 2009-07-08
AR037139A1 (es) 2004-10-27
OA12648A (en) 2006-06-16
NO20040266L (no) 2004-03-24
TNSN04024A1 (en) 2006-06-01
EA005673B1 (ru) 2005-04-28
EP2036890A1 (de) 2009-03-18
UY27410A1 (es) 2003-03-31
PL216066B1 (pl) 2014-02-28
NZ541341A (en) 2007-02-23
SI2157083T1 (sl) 2016-01-29
NZ531558A (en) 2005-12-23
KR20040030903A (ko) 2004-04-09
ZA200401806B (en) 2005-06-29
SI1432683T1 (sl) 2006-04-30
NO20082330L (no) 2004-03-24
DK1432683T3 (da) 2006-03-06
IL164648A0 (en) 2005-12-18
RS11304A (en) 2007-02-05
PL369522A1 (en) 2005-05-02
ITMI20011726A0 (it) 2001-08-06
ITMI20011726A1 (it) 2003-02-06
HK1067123A1 (en) 2005-04-01
KR100626819B1 (ko) 2006-09-20
DE60206787D1 (de) 2006-03-02
EP1432683A1 (de) 2004-06-30
CN1538957A (zh) 2004-10-20
RS52161B (en) 2012-08-31
IL164648A (en) 2007-02-11
HU229563B1 (en) 2014-02-28
ES2212759T1 (es) 2004-08-01
EP1432683B9 (de) 2006-01-18
CY1109711T1 (el) 2014-08-13
CN101475524B (zh) 2012-08-29
EP2157083A2 (de) 2010-02-24
ATE453624T1 (de) 2010-01-15
CY1117051T1 (el) 2017-04-05
KR20050043992A (ko) 2005-05-11
MXPA04001069A (es) 2005-02-17
NO335651B1 (no) 2015-01-19
PT2157083E (pt) 2016-01-22
EP2157083B1 (de) 2015-09-30
HRP20040156B1 (en) 2012-03-31
EP1600441A2 (de) 2005-11-30
EP1600441B1 (de) 2009-12-30
ECSP044973A (es) 2004-06-28
PE20030328A1 (es) 2003-05-09
ES2334678T3 (es) 2010-03-15
HUP0401163A2 (hu) 2004-09-28
CN100448847C (zh) 2009-01-07
MEP2908A (en) 2010-10-10
AP1766A (en) 2007-08-10
ES2555213T3 (es) 2015-12-29
JP2005504045A (ja) 2005-02-10
BR0211739A (pt) 2004-09-28
KR100667687B1 (ko) 2007-01-12
EP1432683B1 (de) 2005-10-19
PT1600441E (pt) 2010-01-20
ME01525B (de) 2011-02-10
HK1086263A1 (en) 2006-09-15
AU2002327924C1 (en) 2009-12-10
EP1600441A3 (de) 2005-12-07

Similar Documents

Publication Publication Date Title
DE60234961D1 (de) Kristallform von Lercanipidin-Hydrochlorid zur Verwendung als antihypertensives Mittel
ATE335722T1 (de) Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel
ATE370123T1 (de) 3-cyanochinoline als inhibitoren von egf-r- und her2-kinasen
DE60324166D1 (de) Dihydropyridinderivaten zur verwendung als inhibitoren der menschlichen neutrophilenelastase
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DE60221233D1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
DE60219682D1 (de) Harnstofe von 2-aminobenzothiazolen als adenosin-modulatoren
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
NO20025488D0 (no) Stabiliserte tetrasoliumreagenssammensetninger og fremgangsmÕter for deres anvendelse
NO20025489D0 (no) Stabiliserte tetrasolium-fenasin-reagens-sammensetninger og fremgangsmÕter for deres anvendelse
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
DE60044004D1 (de) Verwendung von Omega-Carboxyaryl-substituierten Diphenylharnstoffen als raf-Kinase-Inhibitoren
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
DE60210612D1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
DE60211106D1 (de) Zusammensetzung zur Oxidationsfärbung von Keratinfasern
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE60018539D1 (de) Zinkoxid als Plasminogen-Aktivator-Inhibitoren zur äusserlichen Verwendung
ATE302781T1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
DE50311406D1 (de) Verwendung von Formkörpern
ATE402761T1 (de) Katalysatorzusammensetzung und verfahren unter verwendung dieser zusammensetzung
ATE412637T1 (de) Pyrimidin derivate zur verwendung als selektive cox-2 inhibitoren

Legal Events

Date Code Title Description
8363 Opposition against the patent